CYTK Cytokinetics Inc

nothing landing on the FDA clock today and the next 7 days stay quiet too imo. NRXP already landed early, approved Oct 30 ahead of its Nov 10 goal, so that date is off the board the next cluster is Nov 14, a Saturday so Friday is the practical window. $CYTK aficamten MAPLE HCM label, $SMMT ivonescimab in EGFR lung cancer, and $TEVA dexmedetomidine for at home agitation. three dates, one weekend, plenty to prep for

down about 12% today and $CYTK still has the busiest 9 days on the calendar imo Q3 beat yesterday, MYQORZO sales up 76% quarter over quarter to 44.5 million. Nov 14 is the MAPLE PDUFA, aficamten vs metoprolol for the label tomorrow brings the ACACIA late breakers in Chicago, then a Stifel fireside Nov 10. the print got punished, the dates didn't move

six days to Nov 14 and $CYTK is sitting right on its 52 week low aficamten label decision in the MAPLE study, head to head against metoprolol and the data already showed it winning on exercise capacity Q3 MYQORZO sales jumped 76% quarter over quarter to 44.5 million, launch is actually working a label expansion plus a launch that is compounding, imo the washout into the date is the setup

$CYTK Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.37 up 46.27% YoY • Reported revenue of $47.56M up 2351.55% YoY • Cytokinetics reaffirmed full-year 2026 guidance for GAAP combined R&D and SG&A expense of $860M to $890M and non-cash stock-based compensation expense of $140M to $130M.

Latest company news, October 19, 2026: Health Canada authorized MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III) in adults, according to Cytokinetics. Cytokinetics ($CYTK) Stock Hub: November 14 PDUFA, MYQORZO Deeper dive in our hub. Not investment advice.

$CYTK Slew of CV trial fails lately. It makes this asset much more valuable. BP needs to buy this.

$CYTK Ahhh just chillin this morning..., just waiting for AH or first thing in the morning tomorrow...ladadi ladada😻

$CYTK $COGT My two that I think will pass with flying colors. Pdufalina pastries First, we have CYTK Friday AH 🤫😘💎

$CYTK Another good earnings report and also has conference presentations Friday. Prescription base growing at around 3000 new patients a quarter and shooting for over 1/2 of them to be new to brand. 1.6B in cash and investmets on balance sheet so almost no risk of dilution. Nov 14 PDufa for label expansion and about to submit an sNda to double their TAM to nHCM vs just oHCM today. nHCM currently has no approved thearapies. This may be a slow growth investment or it might get bought out soon. I don't mind either :) not investment advice blah blah..

William Blair🏁 $CYTK and said -- We are initiating coverage of Cytokinetics with an Outperform rating, and our DCF-based valuation is $101/share. $EWTX $BMY TECX TENX AZN NVO BAYRY William Blair added—Cytokinetics is a commercial-stage specialty cardiology company built around muscle biology and its first approved product, MYQORZO. Our CYTK call: We have conviction in a strong MYQORZO launch through 2027. Around mid-2027, we model nHCM approval, assuming priority review, adding ~100K addressable patients. We estimate 2032 sales of ~$3.74B.